Actos Sales Data
Last updated: May 2013 (updated quarterly).
The following data shows Actos U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q3 2012 | 39 ( 18) |
$333,494 | -41.96% | 929 | -46.64% |
| Q2 2012 | 21 | $574,553 | -8.94% | 1,741 | -8.94% |
| Q1 2012 | 21 (3) |
$630,970 | -4.52% | 1,912 | -12.97% |
| Q4 2011 | 18 (3) |
$660,834 | -15.22% | 2,197 | -19.67% |
| Q3 2011 | 15 (6) |
$779,504 | -11.05% | 2,735 | -12.03% |
| Q2 2011 | 9 | $876,359 | -13.56% | 3,109 | -4.89% |
| Q1 2011 | 9 | $1,013,886 |  |
3,269 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| June 16, 2011 | Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA |
| June 16, 2011 | Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer |
| June 16, 2011 | Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of Actos (pioglitazone HCl) |
| September 20, 2010 | US Agency Probes Risks Of Bladder Cancer With Diabetes Pill Actos, Rival To Glaxo's Avandia |
| February 15, 2010 | Diabetes Drugs Avandia, Actos Tied to Fractures in Women |
| August 18, 2009 | Avandia Raises Heart Failure Risk More Than Actos |
| December 10, 2008 | 2 Diabetes Drugs Double Fracture Risk in Women |
| December 10, 2008 | Popular Class of Diabetes Drugs Doubles Risk of Fractures in Women |
| November 24, 2008 | Avandia's Heart Risk Higher Than Others in Its Class |
